Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ATP4A | P20648 | 1/20 | 0.36 |
| ▸ | ATP4B | P51164 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18849864 | 1.00 | POLB (0.41) | POLBABCB1CTSLCTSBCTSS | |
| SCHEMBL18849869 | 0.82 | POLB (0.39) | POLBABCB1CTSLCTSBCTSS | |
| SCHEMBL20550620 | 0.82 | POLB (0.39) | POLBABCB1CTSLCTSBCTSS | |
| SCHEMBL22326415 | 0.78 | KMT2A (0.37) | POLBRXFP1 | |
| SCHEMBL18849710 | 0.75 | BTK (0.41) | ABCB1CTSLCTSBCTSSCTSK | |
| SCHEMBL20550691 | 0.75 | BTK (0.41) | ABCB1CTSLCTSBCTSSCTSK | |
| SCHEMBL28611168 | 0.70 | POLB (0.44) | POLBABCB1CTSLCTSBCTSS | |
| SCHEMBL2323323 | 0.69 | OPRD1 (0.43) | POLB | |
| SCHEMBL8276259 | 0.69 | ABCB1 (0.56) | ABCB1CTSLCTSBCTSSCTSK | |
| SCHEMBL18849866 | 0.68 | POLB (0.42) | POLBABCB1CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110088-B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | ACERTA PHARMA B.V. (NL) | 2021-09-07 | — | — | US | disclosed |
| EP-3865485-A1 | IMIDAZOPYRAZINE INHIBITORS OF BRUTON'S TYROSINE KINASE | Acerta Pharma B.V. (NL) | 2021-08-18 | — | — | EP | disclosed |
| US-20200330461-A1 | Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase | ACERTA PHARMA B.V. (NL) | 2020-10-22 | — | — | US | disclosed |
| US-10736893-B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | ACERTA PHARMA B.V. (NL) | 2020-08-11 | — | — | US | disclosed |
| US-20180318297-A1 | Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase | ACERTA PHARMA B.V. (NL) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736893-B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | BTK, LCK, SYK | POLB 2643/4885ABCB1 1973/4885CTSL 4223/4885 |
| US-20200330461-A1 | Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase | BTK, LCK, SYK | POLB 2643/4885ABCB1 1973/4885CTSL 4223/4885 |
| US-20180318297-A1 | Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase | BTK, LCK, SYK | POLB 2643/4885ABCB1 1973/4885CTSL 4223/4885 |
| US-11110088-B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | BTK, LCK, SYK | POLB 2643/4885ABCB1 1973/4885CTSL 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.